Broadfin Capital’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Broadfin Capital’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-500,000	Closed	-$3.73M	–	67
2018 Q1	$3.73M	Buy	+500,000	New	+$3.32M	0.58%	39
2017 Q2	–	Sell	-250,000	Closed	-$2.36M	–	63
2017 Q1	$2.36M	Buy	+250,000	New	+$2.5M	0.29%	46
2015 Q3	–	Sell	-600,000	Closed	-$4.48M	–	100
2015 Q2	$4.48M	Sell	600,000 -300,000	-33%	-$1.81M	0.24%	76
2015 Q1	$5.38M	Buy	900,000 +700,000	+350%	+$4.41M	0.42%	60
2014 Q4	$1.51M	Buy	+200,000	New	+$1.2M	0.13%	74

Other funds holding PGNX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CTA

Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Broadfin Capital's PGNX Position: Q4 2019 in Review

Broadfin Capital increased its Progenics Pharmaceuticals Inc (PGNX) stake by 93% in Q4 2019, buying an estimated $7.81M and bringing the position to 3,060,923 shares worth $15.6M. The position accounts for 2.09% of the portfolio, ranked #14.

Broadfin Capital first reported a position in PGNX in Q2 2013 and has held it in 19 quarters since. The position peaked at $77.3M in Q4 2016. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

Broadfin Capital held 3,060,923 shares of Progenics Pharmaceuticals Inc worth $15.6M as of Q4 2019.
Broadfin Capital bought 1,476,998 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $7.81M.
Progenics Pharmaceuticals Inc made up 2.09% of Broadfin Capital's portfolio in Q4 2019, its #14 holding.
Broadfin Capital first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and has held it in 19 quarters since.
Broadfin Capital's Progenics Pharmaceuticals Inc position peaked at $77.3M in Q4 2016.
128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.